Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has announced the satisfaction of $160,000 in accrued interest on its convertible debentures through the issuance of 320,000 common shares to debenture holders. The Montreal-based biotechnology company also disclosed receipt of a third settlement payment under its sharing agreement with Sorbie Bornholm LP. The dual update provides investors with a clearer picture of the company's current capital obligations and cash-generating arrangements as it advances its proprietary Accum® drug-delivery platform.

Key Points

  • Defence Therapeutics Inc. (CSE: DTC) is a Montreal-based biotechnology company listed on the CSE, OTCQB, and FSE.
  • The company issued 320,000 common shares to satisfy $160,000 in accrued interest on $2,000,000 in convertible debentures bearing 8% per annum interest.
  • A third settlement of $190,670.42 was received from Sorbie Bornholm LP as of October 14, 2026, with 15 settlement payments remaining and 9,090,911 placement shares still held in escrow.
  • Investors may be watching how ongoing share issuances for interest payments affect dilution alongside continued Sorbie Bornholm settlement receipts.

Convertible Debenture Interest Settled in Defence Therapeutics Common Shares

In accordance with the terms of convertible debentures dated September 15, 2025, Defence Therapeutics issued 320,000 common shares to satisfy $160,000 in accrued and unpaid interest. The debentures carry a principal amount of $2,000,000 and bear interest at 8% per annum. The release states that the newly issued Interest Shares are subject to a statutory hold period of four months plus one day under applicable Canadian securities laws. The immediate share price impact was not clear from available public information.

Third Sorbie Bornholm LP Settlement Received in October 2026

The company also updated investors on its sharing agreement with Sorbie Bornholm LP, originally dated March 6, 2026. Defence Therapeutics confirmed receipt of a third settlement payment of $190,670.42, with a settlement date of October 14, 2026, made against 606,060 placement shares released to Sorbie Bornholm LP. As of the announcement date, 9,090,911 placement shares remain held in escrow under the agreement, and the disclosure states that 15 settlement payments are still outstanding, suggesting a continued schedule of future receipts tied to the arrangement.

Accum® Platform Underpins Defence Therapeutics' Broader Oncology Programme

Defence Therapeutics is a publicly traded biotechnology company focused on developing next-generation precision oncology therapeutics through its proprietary Accum® drug-delivery platform. While the current announcement pertains solely to the company's financing and settlement activities, the Accum® platform remains central to its corporate identity and investor proposition. Investors may be watching how the company manages its capital structure, including debenture obligations and share issuances, as it continues to progress its oncology pipeline.